Share on StockTwits

Chimerix (NASDAQ:CMRX) CFO Timothy W. Trost sold 5,000 shares of Chimerix stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $25.13, for a total value of $125,650.00. Following the sale, the chief financial officer now directly owns 629 shares of the company’s stock, valued at approximately $15,807. The transaction was disclosed in a filing with the SEC, which is available at this link.

A number of analysts have recently weighed in on CMRX shares. Analysts at Morgan Stanley cut their price target on shares of Chimerix from $34.00 to $33.00 in a research note on Monday. Separately, analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Tuesday, July 8th. They set a “buy” rating and a $33.00 price target on the stock. Finally, analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Monday, June 23rd. They set a “buy” rating and a $33.00 price target on the stock. Four research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $33.25.

Shares of Chimerix (NASDAQ:CMRX) traded up 0.51% on Tuesday, hitting $25.53. The stock had a trading volume of 91,834 shares. Chimerix has a 52 week low of $12.96 and a 52 week high of $27.69. The stock has a 50-day moving average of $22.60 and a 200-day moving average of $21.12. The company’s market cap is $910.6 million.

Chimerix (NASDAQ:CMRX) last released its earnings data on Thursday, August 7th. The company reported ($0.39) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.44) by $0.05. Analysts expect that Chimerix will post $-1.68 EPS for the current fiscal year.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Receive News & Ratings for Chimerix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.